Pulse Biosciences (PLSE) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
6 Nov, 2026Executive summary
NANOPULSE-AF completed enrollment three months ahead of plan, with 169 evaluable patients across 15 sites; pre-commercial preparation and launch readiness advanced.
Strategic focus remains nsPFA cardiac devices for AF, supported by a portfolio of more than 285 owned patents.
Financial highlights
Q3 revenue was $395,000 versus $86,000 YoY, primarily from limited-release Vybrance sales; commercial case volume increased sequentially.
Q3 GAAP costs and expenses were $24.7M versus $20.5M YoY; non-GAAP costs and expenses were $19.1M versus $14.6M.
GAAP net loss was $23.1M versus $19.4M YoY; non-GAAP net loss was $17.5M versus $13.5M.
Operating cash use was $15.3M versus $13.0M YoY and $18.7M in Q2; cash, cash equivalents and marketable securities totaled $189.2M at September 30, 2026.
Cost of product revenue was $191,000; disposable gross margins are expected to exceed 70% at scale.
Outlook and guidance
Final NANOPULSE-AF data, based on blended six- and 12-month follow-up, are expected in Q3 2027; CE Mark approval is anticipated in Q4 2027.
Launch preparation targets a launch beginning in early 2028, including manufacturing scale-up, market access, supply-chain and marketing plans.
Persistent-AF IDE submission is planned for Q4 2026; NANOCLAMP-AF enrollment is on track to finish by the end of H1 2027.
Quarterly non-GAAP costs and expenses are expected to rise 15%–25% above the Q2 and Q3 average, primarily for EP catheter activities.
PRECISE-BTN follow-up data are expected during 2027 to support a planned 510(k) submission for a benign thyroid nodule indication.
Latest events from Pulse Biosciences
- Pivotal AF enrollment is complete, with U.S. approval targeted for early 2028.PLSE
Stifel 2026 Healthcare Conference 2026 - nsPFA technology delivers breakthrough efficacy in AFib and is poised for broad clinical adoption.PLSE
Canaccord Genuity's 46th Annual Growth Conference - nsPFA delivers superior ablation outcomes with robust IP and strong clinical and financial momentum.PLSE
Investor presentation - Pivotal trial enrollment accelerated, cash rose to $101.6M, and net loss reached $24.7M.PLSE
Q2 2026 - Directors and auditor ratified as company advances AFib trial and strengthens leadership.PLSE
AGM 2026 - Nanosecond PFA platform shows superior efficacy and is on track for early 2028 launch.PLSE
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Nanosecond PFA shows strong clinical promise in AFib, with accelerated pivotal study progress.PLSE
Bank of America Global Healthcare Conference 2026 - Accelerated pivotal trial progress, strong data, and $18.6M net loss with $0.4M revenue.PLSE
Q1 2026 - Advanced pivotal clinical programs in AF ablation with rising losses and modest initial revenue.PLSE
Q4 2025